ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its "neffyinSchools" program in January 2025.
The neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. Each participating school will receive two cartons (four single-use doses) of neffy 2mg for adults and children weighing over 66 lbs.
This initiative is expected to drive wider adoption and usage of neffy in schools across the country, potentially saving lives by ensuring prompt access to epinephrine in cases of severe allergic reactions. Investors appear to view the neffyinSchools program as a positive development that could expand neffy's market reach and boost future sales growth for ARS Pharmaceuticals.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。